[Heart and cancer: cardio-oncology].

Herz und Krebs: Kardioonkologie.

Publisher: Urban Und Vogel Country of Publication: Germany NLM ID: 7801231 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1615-6692 (Electronic) Linking ISSN: 03409937 NLM ISO Abbreviation: Herz Subsets: MEDLINE

Publication: Munchen : Urban Und Vogel
Original Publication: München, Urban & Schwarzenberg.

Cardiovascular Diseases*/diagnosis ; Cardiovascular Diseases*/epidemiology ; Cardiovascular Diseases*/therapy ; Neoplasms*/epidemiology ; Neoplasms*/therapy ; Neoplasms*/complications; Humans ; Cardio-Oncology ; Cardiotoxicity ; Medical Oncology

Cardiovascular diseases and cancer have a complex relationship and show a reciprocal linkage and influence. Mutual risk factors, demographic changes and increasing multimorbidity result in an increase in the incidence of both diseases. Advances in oncological and cardiological treatment lead to a further increase in patients with cured or chronic diseases as a relevant comorbidity. The induction of cardiovascular side effects by cancer therapies leads to increased cardiovascular morbidity and mortality in cancer patients. Recent data also show that cardiovascular disease, through various factors, can also promote the development and progression of cancer. An understanding of the interrelationship between cardiovascular diseases and cancer can be seen as a major medical challenge for the future. To this end, scientific, structural, clinical and educational interfaces between cardiology and oncology are essential. This article outlines the complex relationships between cardiovascular diseases and cancer and defines current and future challenges for the best possible care of affected patients.
(© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)

(DESTATIS) SB (2021) Todesursachen in Deutschland. https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Todesursachen/_inhalt.html . Zugegriffen: 11. Nov. 2023.
Michel L, Schadendorf D, Rassaf T (2020) Oncocardiology: new challenges, new opportunities. Herz: 1–6.
(DESTATIS) SB (2022) Mitten im demographsichen Wandel. https://www.destatis.de/DE/Themen/Querschnitt/Demografischer-Wandel/demografie-mitten-im-wandel.html . Zugegriffen: 2011.
Krebsregisterdaten) RKIZf (2023) Krebs in Deutschland 2017/2018. https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_inhalt.html . Zugegriffen: 11. Nov. 2023.
Herzstiftung D (2021) Herzbericht 2021. https://herzstiftung.de/service-und-aktuelles/publikationen-und-medien/herzbericht . Zugegriffen: 11. Nov. 2023.
Rassaf T, Lehmann L (2020) Cardio-Oncology in Germany. https://www.escardio.org/Councils/council-of-cardio-oncology/cardio-oncology-in-germany.
Rassaf T, Totzeck M, Backs J, Bokemeyer C et al (2020) Onco-cardiology: consensus paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol.
Lyon AR, López-Fernández T, Couch LS, Asteggiano R et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229–4361. (PMID: 10.1093/eurheartj/ehac24436017568)
Aboumsallem JP, Moslehi J, de Boer RA (2020) Reverse cardio-oncology: cancer development in patients with cardiovascular disease. J Am Heart Assoc 9(2):e13754. (PMID: 10.1161/JAHA.119.013754319607367033852)
Michel L, Totzeck M, Rassaf T (2023) 2022 ESC guidelines on cardio-oncology: understanding and treating cardiovascular side effects from cancer therapy. Herz 48(1):15–22. (PMID: 10.1007/s00059-022-05149-z36441175)
Michel L, Helfrich I, Hendgen-Cotta UB, Mincu RI et al (2022) Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. Eur Heart J 43(4):316–329. (PMID: 10.1093/eurheartj/ehab43034389849)
Shi S, Lv J, Chai R, Xue W et al (2023) Opportunities and challenges in cardio-oncology: a bibliometric analysis from 2010 to 2022. Curr Probl Cardiol 48(8):101227. (PMID: 10.1016/j.cpcardiol.2022.10122735500730)
Totzeck M, Schuler M, Stuschke M, Heusch G et al (2019) Cardio-oncology—strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol 280:163–175. (PMID: 10.1016/j.ijcard.2019.01.03830661849)
Dempsey N, Rosenthal A, Dabas N, Kropotova Y et al (2021) Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat 188(1):21–36. (PMID: 10.1007/s10549-021-06280-x34115243)
Herrmann J, Lenihan D, Armenian S, Barac A et al (2022) Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 43(4):280–299. (PMID: 10.1093/eurheartj/ehab67434904661)
Lyon AR, Yousaf N, Battisti NML, Moslehi J et al (2018) Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19(9):e447–e458. (PMID: 10.1016/S1470-2045(18)30457-130191849)
Michel L, Rassaf T, Totzeck M (2019) Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc 25:100420. (PMID: 315170366736791)
Totzeck M, Michel L, Lin Y, Herrmann J et al (2022) Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. Eur Heart J 43(20):1928–1940. (PMID: 10.1093/eurheartj/ehac106352571579123242)
Lancellotti P, Suter TM, López-Fernández T, Galderisi M et al (2019) Cardio-oncology services: rationale, organization, and implementation. Eur Heart J 40(22):1756–1763. (PMID: 10.1093/eurheartj/ehy45330085070)
Mahmood SS, Fradley MG, Cohen JV, Nohria A et al (2018) Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71(16):1755–1764. (PMID: 10.1016/j.jacc.2018.02.037295672106196725)
Michel L, Rassaf T (2022) Drug-induced cardiomyopathies. Dtsch Med Wochenschr 147(23):1513–1522. (PMID: 36384152)
Lyon AR, Dent S, Stanway S, Earl H et al (2020) Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the cardio-oncology study group of the heart failure association of the European Society of Cardiology in collaboration with the international cardio-oncology society. European J of Heart Fail.
Roderburg C, Loosen SH, Jahn JK, Gänsbacher J et al (2021) Heart failure is associated with an increased incidence of cancer diagnoses. Esc Heart Fail 8(5):3628–3633. (PMID: 10.1002/ehf2.13421341801468497216)
Bertero E, Canepa M, Maack C, Ameri P (2018) Linking heart failure to cancer: background evidence and research perspectives. Circulation 138(7):735–742. (PMID: 10.1161/CIRCULATIONAHA.118.03360330359132)
Ostenfeld EB, Erichsen R, Pedersen L, Farkas DK et al (2014) Atrial fibrillation as a marker of occult cancer. PloS One 9(8):e102861. (PMID: 10.1371/journal.pone.0102861251198804138009)
Seretis A, Cividini S, Markozannes G, Tseretopoulou X et al (2019) Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies. Sci Rep 9(1):8565. (PMID: 10.1038/s41598-019-45014-4311899416561976)
Meijers WC, Maglione M, Bakker SJL, Oberhuber R et al (2018) Heart failure stimulates tumor growth by circulating factors. Circulation 138(7):678–691. (PMID: 10.1161/CIRCULATIONAHA.117.03081629459363)
Avraham S, Abu-Sharki S, Shofti R, Haas T et al (2020) Early cardiac remodeling promotes tumor growth and metastasis. Circulation 142(7):670–683. (PMID: 10.1161/CIRCULATIONAHA.120.04647132475164)
Ridker PM, Everett BM, Thuren T, MacFadyen JG et al (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131. (PMID: 10.1056/NEJMoa170791428845751)
Ridker PM, MacFadyen JG, Thuren T, Everett BM et al (2017) Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390(10105):1833–1842. (PMID: 10.1016/S0140-6736(17)32247-X28855077)

Keywords: Anthracyclines; Cancer; Cardiotoxicity; Cardiovascular diseases; Reverse cardio-oncology
Local Abstract: [Publisher, German] Kardiovaskuläre Erkrankungen und Krebs stehen in einem komplexen Zusammenhang und zeigen eine wechselseitige Verknüpfung und Beeinflussung. Gemeinsame Risikofaktoren, der demographische Wandel und die zunehmende Multimorbidität resultieren in einem vermehrten Auftreten beider Erkrankungen. Fortschritte in der onkologischen und kardiologischen Therapie führen zu einer weiteren Zunahme von Patientinnen und Patienten mit geheilten oder chronischen Erkrankungen als relevanter Komorbidität. Durch die Induktion kardiovaskulärer Nebenwirkungen durch Krebstherapien kommt es zu einer erhöhten kardiovaskulären Morbidität und Mortalität von Krebspatientinnen und Krebspatienten. Neue Daten zeigen zudem, dass auch kardiovaskuläre Erkrankungen über verschiedene Faktoren die Entstehung und das Fortschreiten einer Krebserkrankung begünstigen können. Das Verständnis der wechselseitigen Beziehung zwischen kardiovaskulären Erkrankungen und Krebs kann als eine entscheidende medizinische Herausforderung der Zukunft angesehen werden. Hierfür sind neue wissenschaftliche, strukturelle, klinische und edukative Schnittstellen zwischen Kardiologie und Onkologie als Grundlage zwingend erforderlich. Dieser Artikel skizziert die Zusammenhänge zwischen kardiovaskulären Erkrankungen und Krebs und definiert aktuelle und zukünftige Herausforderungen für eine bestmögliche Versorgung der betroffenen Patientinnen und Patienten.

Date Created: 20240130 Date Completed: 20240307 Latest Revision: 20240307

20240307

10.1007/s00059-024-05232-7

38289420